An Open Label, Multi-center, IRESSA Clinical Access Program of Gefitinib 250 mg (IRESSA) for the continued treatment of patients in the United States currently benefiting or who have benefited from treatment with gefitinib.
Latest Information Update: 05 Jun 2012
At a glance
- Drugs Gefitinib (Primary)
- Indications Lung cancer
- Focus Therapeutic Use
- 05 Jun 2012 New trial record